Morepen Labs Q2 results: Net profit up 38% at Rs 37 crore

"With massive increase in active pharmaceutical ingredient (API) demand globally and more particularly with frequent supply disruptions from China, we are putting our expansion plans for API on fast track," Morepen Laboratories Chairman and MD Sushil Suri said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3c3tHfa
via IFTTT